The FDA has approved a split-dosing regimen of daratumumab for patients with multiple myeloma, providing physicians the option to split the first infusion of the CD38-directed monoclonal antibody over 2 consecutive days or complete in a single session.
Victor A. Chow, MD, discusses the next steps in understanding how to treat patients with large B-cell lymphomas who progress after chimeric antigen receptor T-cell therapy.
Heather Wakelee, MD, shares insight on the current landscape of lung cancer and discussed how immunotherapy and targeted therapy can be improved for patients with non–small cell lung cancer.
The FDA has granted a priority review designation to a supplemental biologics license application for the combination of avelumab and axitinib as a treatment for patients with advanced renal cell carcinoma.
The RAINBOW and TAGS trials have demonstrated strong evidence to support the use of ramucirumab and TAS-102 in patients with advanced gastric or gastroesophageal cancer who have progressed on first-line therapy.
The European Commission has approved brentuximab vedotin for use in combination with chemotherapy as a frontline treatment for adult patients with CD30+ stage IV Hodgkin lymphoma.
Robert L. Talley, MD, discusses current and potential future standards of care in idiopathic thrombocytopenic purpura and thrombotic thrombocytopenic purpura.
The FDA has granted a priority review designation to a supplemental biologics license application for pembrolizumab (Keytruda) alone or in combination with platinum and 5-fluorouracil chemotherapy as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma.
The European Commission has approved dasatinib in combination with chemotherapy for the treatment of pediatric patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia.
Manish A. Shah, MD, discusses the results of the GAMMA-1 trial and challenges that remain for patients with gastric cancer.
Earlier diagnosis and more effective therapeutic options are enabling physicians to deliver better rates of disease control and improved quality of life to patients with hormone receptor–positive, HER2-negative metastatic breast cancer.
Byrne Lee, MD, discusses regional treatment strategies for patients with metastatic colorectal cancer.
The FDA has scheduled an Oncologic Drugs Advisory Committee hearing for February 26, 2019, to discuss a new drug application for selinexor in combination with dexamethasone for the treatment of patients with penta-refractory multiple myeloma.
The FDA has added 3 months to the review period for a supplemental new drug application for ruxolitinib for the treatment of patients with acute graft-versus-host disease who have had an inadequate response to corticosteroids, making the new action date May 24, 2019.
Massimo Cristofanilli, MD, discusses the clinical utility of liquid biopsies—specifically focusing on circulating tumor cells and cell-free DNA—and highlights ongoing research in the space.
Marwan Fakih, MD, discusses recent trials in colorectal cancer and highlights other ongoing research in the field.
Sarah Holstein, MD, PhD, highlights the vast treatment paradigm of myeloma and shared some considerations for sequencing.
Erika P. Hamilton, MD, reflects on the latest data in HER2-positive breast cancer and additional therapies moving through the pipeline.
The relative risk of developing a solid subsequent malignant neoplasm remained elevated in survivors of childhood Hodgkin lymphoma, according to extended follow-up of more than 25 years from the Late Effects Study Group cohort.
Margetuximab in combination with chemotherapy improved progression-free survival compared with trastuzumab and chemotherapy in heavily pretreated patients with metastatic HER2-positive breast cancer.
The FDA has approved the nanobody caplacizumab-yhdp in combination with plasma exchange and immunosuppression for the treatment of adult patients with acquired thrombotic thrombocytopenic purpura, making it the first FDA-approved therapy indicated for this patient population.
Geoffrey R. Oxnard, MD, discusses the use of cell-free DNA as a potential method of cancer detection and subsequent assessment of treatment response in patients with solid and hematologic malignancies.
Komal Jhaveri, MD, discusses the 3 major classes of drugs showing potential in the TNBC pipeline.
The FDA has granted a priority review designation to a new drug application for the investigational, small molecule, CSF1R receptor inhibitor pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor.
Sukhmani Padda, MD, discusses the practice-changing impact of osimertinib and addresses the challenges that still remain in EGFR-positive NSCLC.
Isatuximab in combination with pomalidomide (Pomalyst) and low-dose dexamethasone was shown to prolong progression-free survival compared with pomalidomide and dexamethasone alone in patients with relapsed/refractory multiple myeloma.
Genentech has completed its FDA submission of a supplemental Biologics License Application for ado-trastuzumab emtansine as an adjuvant treatment for patients with HER2-positive early breast cancer who had residual disease following neoadjuvant therapy.
Rachna T. Shroff, MD, MS, highlighted the ongoing research efforts in biliary tract cancers, specifically with cholangiocarcinoma treatment.
John Strickler, MD, discusses how liquid biopsies are being used to help guide treatment decisions for patients with GI cancers and shed light on other research efforts that are being made to improve outcomes.
The European Medicines Agency’s Committee for Medicinal Products for Human Use has adopted a positive opinion for first-line treatment with pembrolizumab in combination with carboplatin and either paclitaxel or nab-paclitaxel in patients with metastatic squamous non–small cell lung cancer.
